Clinical trials: Adenocarcinoma of Rectum
Colorectal Cancer
Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006366
- Testing
- fluorouracil, irinotecan hydrochloride, conventional surgery
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced Rectal Carcinoma
Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer
Rectal cancer is one of the most prevalent malignancies in the world, and its prevalence is rising. In more advanced cases neoadjuvant therapy is advised before to surgery, and radiotherapy is one of its cornerstones.
- Trial name
- TEHRAN (NCT05920928)
- Testing
- Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course radiotherapy with concurrent capecitabine(825mg/m2)
- Volunteers
- 114 people
- Sponsor
- Tehran University of Medical Sciences
Rectal Cancer Stage I
Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma
BACKGROUND: Rectal cancer is the sixth most common neoplasm in Spain. In the early stages (pT1-N0), the treatment of choice is transanal endoscopic microsurgery.
- Trial name
- TAUTEM-pT1 (NCT06218108)
- Testing
- Taulí-T1 versus conventional classifications
- Where
- Spain
- Volunteers
- 317 people
- Sponsor
- Corporacion Parc Tauli
Advanced Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
- Conditions
- Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT00707889
- Testing
- ABT-869, bevacizumab, oxaliplatin
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 159 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Colorectal Cancer
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
This study is being done to compare two types of surgery currently used for rectal cancer. The two types of surgery are laparoscopic-assisted rectal resection and open laparotomy rectal resection.
- Trial name
- NCT00726622
- Testing
- Open laparotomy and rectal resection, Laparoscopic-assisted rectal resection
- Where
- 37 sites in United States, Canada
- Volunteers
- 486 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
This trial is a Phase I study to be conducted in patients with non-MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC) and is divided in two Parts.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- CATRIPCA (NCT03871959)
- Testing
- Pembrolizumab, DEBIO1143
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Leon Berard
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Rectal Adenocarcinoma, High-Risk Cancer
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRIT (NCT06908031)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Adenocarcinoma
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
This study is a prospective, single-arm, single-center study of investigator's choice of total neoadjuvant therapy (TNT) or neoadjuvant chemoradiation in locally advanced rectal cancer.
- Trial name
- NCT04418895
- Testing
- Chemoradiation, short course radiation therapy, mFOLFOX6
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- EXPERT-C (NCT00383695)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- 13 sites in Spain, Sweden and 1 more
- Volunteers
- 164 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the…
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8
- Trial name
- NCT05081024
- Testing
- Biopsy, Biospecimen Collection, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Locally Advanced Rectal Carcinoma
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with…
- Trial name
- MEND-IT II (NCT07472868)
- Testing
- FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 20 sites in Netherlands
- Volunteers
- 394 people
- Sponsor
- J. W. A. Burger
Colorectal Carcinoma, Gastric Carcinoma
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread.
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06882746
- Testing
- BI 765049
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well capecitabine and celecoxib with or without radiation therapy works in treating patients with colorectal cancer that is newly diagnosed or has been previously treated with fluorouracil, and has…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- ADAPT (NCT01729923)
- Testing
- Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Metastatic Colorectal Cancer
Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas
The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.
- Trial name
- CD3-OncoQuant (NCT02364024)
- Volunteers
- 856 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Rectal Neoplasms, Colostomy Stoma
Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal Adenocarcinoma
Aim of this study is to compare the cost-effectiveness and the quality of life in the 6 months following the surgery of a pseudo continent perineal colostomy (PCPC) and a permanent left iliac colostomy (PLIC) following an…
- Conditions
- Rectal Neoplasms, Colostomy Stoma, Quality of Life
- Trial name
- NCT04141566
- Testing
- Perineal pseudocontinent colostomy, Permanent left iliac colostomy
- Where
- Morocco
- Volunteers
- 35 people
- Sponsor
- Moroccan Society of Surgery
Colorectal Neoplasms
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression.
- Trial name
- NCT00313794
- Testing
- CP-675,206
- Where
- 11 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Bortezomib may interfere with the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have…
- Trial name
- NCT00052507
- Testing
- bortezomib
- Where
- 4 sites in Canada
- Sponsor
- University Health Network, Toronto
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Colon Adenocarcinoma, Rectal Adenocarcinoma
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7
- Trial name
- NCT02368886
- Testing
- Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment
- Where
- 22 sites in United States
- Volunteers
- 123 people
- Sponsor
- Academic and Community Cancer Research United